书目名称 | Drug Development in Psychiatry |
编辑 | Matthew Macaluso,Sheldon H. Preskorn,Richard C. Sh |
视频video | |
概述 | Reviews critical elements of both basic and clinical science as they pertain to drug development in psychiatry.It covers both historical elements and modern interpretations to understand best practice |
丛书名称 | Advances in Neurobiology |
图书封面 |  |
描述 | .The book reviews clinical trial methodology as it pertains to drug development in psychiatry. The reader will understand the process of drug development in psychiatry from discovery through marketing with the help of clinically relevant examples. The reader will appreciate the history of drug development in psychiatry dating back to the era of serendipitous discovery and culminating in an era of new and highly focused targets. Readers will understand how drug development in psychiatry has changed and adapted with the discovery of novel mechanism of action drugs. Novel drugs and disease targets have changed the way developers and regulatory agencies think about clinical trial methodology..The book elucidates how biomarkers, genetics and advances in neuroscience and neuroimaging have influenced drug development approaches, which will ultimately change the practice of psychiatry. The book will be broken down into the following sections:.a. Prior to the 1960s - Drug discovery by chance observation.b. The last 50 years – refined targeting of CNS drugs without the discovery of mechanistically new drugs.c. The future – the discovery and development of mechanistically n |
出版日期 | Book 2023 |
关键词 | clinical trial; SPECT; APOE4; fMRI; florbetapir; biomarkers; clinical psychiatry; psychiatric medications |
版次 | 1 |
doi | https://doi.org/10.1007/978-3-031-21054-9 |
isbn_softcover | 978-3-031-21056-3 |
isbn_ebook | 978-3-031-21054-9Series ISSN 2190-5215 Series E-ISSN 2190-5223 |
issn_series | 2190-5215 |
copyright | The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl |